


Deciphering the Prognostic Landscape of Regulated Cell Death in Colorectal Cancer using a Two-Step Machine Learning Framework



Avik Sengupta, Sushree Sangita Kar, Rahul Kumar

CG&T Lab, Dept. of Biotechnology, Indian Institute of Technology Hyderabad, Kandi, Sangareddy, Telangana-502285, India


INTRODUCTION



OBJECTIVES

1. Develop a robust **c-RCDI** risk model from 13 NARCD pathways using a **novel two-step ML framework**.
2. Validate the c-RCDI as a powerful, **independent prognostic factor** against clinical benchmarks.
3. Uncover the **biological and immunological drivers** (oncogenic pathways, immune infiltration) of the high-risk class.
4. Test the c-RCDI's ability to **predict immunotherapy response** and identify **targeted drug sensitivities**.


METHODOLOGY




CONCLUSIONS

1. Developed 43-gene **c-RCDI prognostic risk model** via a novel 2-step ML framework, from non-apoptotic regulated cell death pathways. It robustly stratifies CRC patients (HR=8.29, 5-yr AUROC=0.88).
2. Powerful **independent prognostic factor** (HR=55.1), far exceeding traditional clinical markers like tumor stage (HR=1.5).
3. Biologically coherent: The model captures **core CRC oncogenic pathways** (MYC, EMT) and **immunosuppressive microenvironments**.
4. Identifies novel vulnerabilities by selecting **under-explored genes** (ATP2B4, CHMP6, MAP1B) involved in cellular homeostasis and metabolic resilience.
5. A dual-purpose clinical tool that predicts **immunotherapy failure** (high TIDE score) and guides **targeted therapies** (e.g., CDK/MEK inhibitors).


CLINICAL IMPACT



TOOL DEPLOYMENT




RESULTS




c-RCDI evaluation

Fig. 3: Constitution and performance of the c-RCDI prognostic risk model.




c-RCDI: an independent prognostic factor

Fig. 4: Multivariate Cox Regression and Nomogram analysis.




c-RCDI genes analysis

Fig. 5: PPI Network, CRISPR-Cas9 KO, and single cell gene analyses.




c-RCDI is exclusive to colorectal cancer

Fig. 6: KM Plots for four other cancer types based on the c-RCDI model.




Clinical interpretation of c-RCDI

Fig. 7: Immune Enrichment, TIDE, Drug sensitivity and ML analysis for high- and low-risk classes.




ML feature interpretation

Fig. 8: Top 20 features selected using importance score.



Pathway enrichment risk class analysis

Fig. 9: Top 10 enriched pathways using GSEA for HALLMARK database.



ACKNOWLEDGEMENTS



REFERENCES

1. Avik Sengupta, Sushree Sangita Kar, Rahul Kumar, Non-apoptotic regulated cell death based prognostic risk model for colorectal cancer using machine learning guided two-step framework, Briefings in Bioinformatics, Volume 26, Issue 6, November 2025, bbaf639, <https://doi.org/10.1093/bib/bbaf639>.
2. Cao K, Zhu J, Lu M, et al. Analysis of multiple programmed cell death-related prognostic genes and functional validations of necroptosis-associated genes in oesophageal squamous cell carcinoma. EBioMedicine 2024; 99:104920.